📰 True Human News
Page 3 - True Human News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from True Human. Real-time updates on events, politics, business and more.
October 13, 2022
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in FranceAUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE)
May 21, 2022
XBiotech (NASDAQ:XBIT – Get Rating) and PTC Therapeutics (NASDAQ:PTCT – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends. Profitability This table compares XBiotech and PTC Therapeutics’ net margins, return […]
April 28, 2022
ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in FranceAUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the French
February 2, 2022
XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & JohnsonAUSTIN, Texas, Feb. 02, 2022 (GLOBE NEWSWIRE) --
January 26, 2022
Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic DiseaseAUSTIN, Texas, Jan. 26, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc.
January 26, 2022
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQNatrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic DiseaseAUSTIN, Texas, Jan. 26, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASD...
October 28, 2021
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After StrokeAUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced
April 19, 2021
(1) XBiotechs New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer AUSTIN, Texas, April 19, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the FDA has granted permission to commence clinical trials with its novel drug candidate for treating patients with pancreatic cancer. From 1992 to 2018 the death rate from pancreatic cancer steadily increased in the USA. It is now predicted that pancreatic cancer will claim 48,220 lives and be the 3 rd leadi...
January 21, 2021
XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain January 21, 2021 08:15 ET | Source: XBiotech Inc. XBiotech Inc. Austin, Texas, UNITED STATES AUSTIN, Texas, Jan. 21, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: ...
January 21, 2021
Investegate announcements from XBiotech Inc., XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain